Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Angiotensin receptor blockers vs placebo or no treatment Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.44 [0.23, 0.85] | 5 studies · 815 participants | Low |
Angiotensin receptor blockers vs placebo or no treatment Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 5.58 [0.85, 36.81] | 4 studies · 671 participants | Very low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors All‐cause death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.13 [0.68, 1.88] | 15 studies · 1739 participants | Low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Cardiovascular death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.15 [0.45, 2.98] | 13 studies · 1606 participants | Low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Doubling of SCr Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.88 [0.52, 1.48] | 2 studies · 767 participants | Low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Fatal or nonfatal stroke Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.92 [0.38, 2.24] | 5 studies · 1146 participants | Low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Fatal or nonfatal myocardial infarction Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.25 [0.62, 2.5] | 6 studies · 1209 participants | Low |
Angiotensin‐converting‐enzyme inhibitors vs placebo or no treatment Cardiovascular death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.67 [0.13, 3.57] | 17 studies · 5625 participants | Very low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.97 [0.67, 1.42] | 965 participants | Low |
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.96 [0.62, 1.48] | 4 studies · 216 participants | Low |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment All‐cause death1 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | 1 study · 90 participants | Low |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Cardiovascular death4 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | 1 study · 90 participants | Low |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Micro‐ to macroalbuminuria5 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | 0.1 [0.05, 0.24] | 1 study · 82 participants | Low |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Micro‐ to normoalbuminuria6 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 5.27 [0.34, 81.57] | 1 study · 82 participants | Very low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers All‐cause death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.08 [0.49, 2.4] | 6 studies · 1166 participants | Low |
Angiotensin‐converting‐enzyme inhibitors vs placebo or no treatment Doubling of SCr Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.69 [0.47, 1.01] | 8 studies · 6702 participants | Very low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers Cardiovascular death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 3.02 [0.61, 14.85] | 4 studies · 994 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers Doubling of SCr Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.14 [0.7, 1.85] | 2 studies · 813 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers Fatal or nonfatal stroke Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.72 [0.23, 2.24] | 2 studies · 775 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers Fatal or nonfatal myocardial infarction Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.44 [0.17, 1.12] | 3 studies · 880 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.25 [0.67, 2.32] | 3 studies · 958 participants | Very low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) alone vs ACEi plus angiotensin receptor blockers Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.08 [0.74, 1.57] | 3 studies · 145 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB All‐cause death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.02 [0.76, 1.37] | 7 studies · 2607 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB Cardiovascular death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 3.03 [0.62, 14.93] | 4 studies · 992 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB Doubling of SCr Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.18 [0.85, 1.64] | 3 studies · 2252 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB Fatal or nonfatal stroke Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.76 [0.35, 1.65] | 3 studies · 2223 participants | Low |
Angiotensin‐converting‐enzyme inhibitors vs placebo or no treatment Fatal or nonfatal stroke Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.02 [0.8, 1.31] | 2 studies · 4944 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB Fatal or nonfatal myocardial infarction Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.7 [0.49, 1.01] | 4 studies · 2321 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.07 [0.77, 1.49] | 4 studies · 2410 participants | Low |
Angiotensin receptor blockers (ARB) alone vs angiotensin‐converting‐enzyme inhibitors plus ARB Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.04 [0.74, 1.45] | 3 studies · 151 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi All‐cause death1 Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | 3 studies · 269 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Cardiovascular death4 Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | 3 studies · 269 participants | Low |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Micro‐ to macroalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Micro‐ to normoalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors vs placebo or no treatment Fatal or nonfatal myocardial infarction Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.79 [0.57, 1.09] | 3 studies · 5100 participants | Low |
Angiotensin receptor blocker (ARB) vs another ARB All‐cause death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.58 [0.05, 7.08] | 5 studies · 2041 participants | Very low |
Angiotensin receptor blocker (ARB) vs another ARB Cardiovascular death Median · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.34 [0.47, 3.82] | 4 studies · 1360 participants | Low |
Angiotensin receptor blocker (ARB) vs another ARB Doubling of SCr4 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1 [0.2, 4.94] | 1 study · 857 participants | Low |
Angiotensin receptor blocker (ARB) vs another ARB Fatal or nonfatal stroke6 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 2.21 [0.77, 6.29] | 1 study · 857 participants | Low |
Angiotensin receptor blocker (ARB) vs another ARB Fatal or nonfatal myocardial infarction7 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.36 [0.12, 1.14] | 1 study · 857 participants | Low |
Angiotensin receptor blocker (ARB) vs another ARB Micro‐ to macroalbuminuria 8 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 1.34 [0.87, 2.07] | 1 study · 716 participants | Low |
Angiotensin receptor blocker (ARB) vs another ARB Micro‐ to normoalbuminuria9 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | RR 0.98 [0.25, 3.88] | 1 study · 716 participants | Low |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB All‐cause death1 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | 2 studies · 156 participants | Low |
Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB Cardiovascular death4 · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | 2 studies · 156 participants | Low |